Publish time: 2022-03-28 00:00:00
The present disclosure provides compounds that inhibit MCM, for example, MCM2. The compounds described herein may be useful in treating diseases asssocated with MCM (e.g., any one of MCM2-MCM7), for example, proliferative diseases such as cancer (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing’s sarcoma, osteosarcoma, brain cancer, neuroblastoma). The compounds described herein may be useful in treating infectious diseases, such as bacterial infections, and useful in alleviating inflammatory conditions. Also provided are pharmaceutical compositions, kits, methods, and uses of any of the compounds described herein.
DNA replication has traditionally been an important target for cancer treatment. This invention provides compounds that inhibit MCM, such as MCM2. The compounds can be used to treat diseases related to MCM, such as proliferative diseases, such as cancer and infectious disease
28A-1041219
TW I744288、US 11,434,229 B2、US 11,919,886 B2
- Cancer treatment
- Infectious disease treatment
Chi-Huey Wong, Rong-Jie Chen, Ting-Jen Cheng, Pan-Chyr Yang, and Szu-Hua Pan
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives for the treatment of proliferative diseases and infectious diseases